Aclaris Therapeutics Inc (ACRS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aclaris Therapeutics Inc (ACRS) has a cash flow conversion efficiency ratio of -0.091x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.93 Million) by net assets ($120.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Aclaris Therapeutics Inc for the company's overall valuation and market capitalisation.
Aclaris Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Aclaris Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aclaris Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aclaris Therapeutics Inc ranked by their cash flow conversion efficiency. See ACRS debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhuhai Winbase International Chemical Tank Terminal Co Ltd
SHE:002492
|
0.022x |
|
Plasson Indus
TA:PLSN
|
0.068x |
|
TVZone Media Co Ltd
SHG:603721
|
0.010x |
|
Hiyes International Co Ltd
TW:2348
|
0.010x |
|
Ferm. Casino Mun. Canne
PA:FCMC
|
0.020x |
|
ENDOMINES FINLAND OYJ EO1
F:H13
|
N/A |
|
Alltek Technology Corp
TW:3209
|
-0.311x |
|
Siward Crystal Technology Co Ltd
TW:2484
|
0.029x |
Annual Cash Flow Conversion Efficiency for Aclaris Therapeutics Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Aclaris Therapeutics Inc from 2013 to 2024. View Aclaris Therapeutics Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $155.55 Million | $-20.07 Million | -0.129x | +74.10% |
| 2023-12-31 | $157.18 Million | $-78.33 Million | -0.498x | -45.75% |
| 2022-12-31 | $197.62 Million | $-67.57 Million | -0.342x | -29.42% |
| 2021-12-31 | $197.34 Million | $-52.13 Million | -0.264x | +74.25% |
| 2020-12-31 | $37.65 Million | $-38.63 Million | -1.026x | +25.62% |
| 2019-12-31 | $69.91 Million | $-96.44 Million | -1.380x | -194.38% |
| 2018-12-31 | $215.12 Million | $-100.81 Million | -0.469x | -93.11% |
| 2017-12-31 | $225.26 Million | $-54.66 Million | -0.243x | -18.86% |
| 2016-12-31 | $169.49 Million | $-34.60 Million | -0.204x | +7.27% |
| 2015-12-31 | $92.52 Million | $-20.37 Million | -0.220x | -159.84% |
| 2014-12-31 | $-20.75 Million | $-7.64 Million | 0.368x | -31.48% |
| 2013-12-31 | $-9.16 Million | $-4.92 Million | 0.537x | -- |
About Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its … Read more